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Abstract  
Background. Descriptive data on Pneumocystis jirovecii pneumonia (PJP) in solid organ transplant 
recipients (SOTr) in the era of routine Pneumocystis-prophylaxis are lacking.  
Methods. All adult SOTr between 2008-2016 were included. PJP was diagnosed based on consensus 
guidelines. Early-onset PJP was defined as PJP within the 1st-year-post-transplant.  
Results. 41/2842 SOTr (1.4%) developed PJP (incidence rate: 0.01/1000 person-days) at a mean of 
493-days post-transplant: 21 (51.2%) early vs 20 (48.8%) late-onset PJP. 2465 (86.7%) SOTr received 
Pneumocystis-prophylaxis for a mean 316 days. PJP incidence was 0.001% and 0.003% (log-
rank<0.001) in SOTr with and without Pneumocystis-prophylaxis, respectively. PJP was an early event 
in 10/12 (83.3%) SOTr who did not receive Pneumocystis-prophylaxis and developed PJP, compared 
to those patients who received prophylaxis (11/29, 37.9%; P-value: 0.008). Among late-onset PJP 
patients, most cases (13/20, 65%) were observed during the 2nd year post-transplant. Age ≥65 years 
(OR: 2.4, P-value: 0.03) and CMV infection during the first 6 months post-SOT (OR: 2.5, P-value: 
0.006) were significant PJP predictors, while Pneumocystis-prophylaxis was protective for PJP (OR: 
0.3, P-value: 0.006) in the overall population. Most patients (35, 85.4%) were treated with 
trimethoprim-sulfamethoxazole for a mean 20.6 days. 1-year mortality was 14.6%.  
Conclusions. In the Pneumocystis-prophylaxis-era, PJP remains a rare post-transplant complication. 
Most cases occurred post-PJP-prophylaxis-discontinuation, particularly during the 2nd-year-post-
transplant. Additional research may help identify indications for Pneumocystis-prophylaxis 
prolongation.  
 
Background  
Pneumocystis jirovecii pneumonia (PJP) is a rare complication in solid organ transplant recipients 
(SOTr), as a result of routine Pneumocystis-prophylaxis applied in most transplant centers (1-7). In 
the absence of effective prophylaxis, 5-15% SOTr may develop PJP post-transplant (2, 4, 8-10). Most 
experts and existing guidelines agree that Pneumocystis-prophylaxis should be administered for 12 
months (Europe) to indefinitely (United States of America, USA) in lung and heart transplant 
recipients, and for 3-6 months (Europe) or 6-12 months post-transplant (USA) post-kidney or liver 
transplant (4, 8, 11, 12). Furthermore, reinstitution or prolongation of Pneumocystis-prophylaxis may 
be required in SOTr with persistently high immunosuppression, prior history of PJP, recent rejection 
episodes or cytomegalovirus (CMV) infection (4, 8, 13, 14). However, large variability in prophylactic 
strategies exists across different SOT centers worldwide, which may impact the epidemiology of this 
infection post-transplant (1, 7, 15). We performed a retrospective study to describe the 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
epidemiology, timing, risk factors and outcomes of PJP using the Swiss Transplant Cohort Study 
(STCS) between 2008 and 2016.  
 
Methods 
Study design and objectives. The STCS is a prospective national cohort, in which all SOTr in 
Switzerland, who sign a written informed consent are registered, representing >95% of SOTr (16). 
Transplant activity is shared between six main institutions: all centers perform kidney transplants, 
whereas heart, liver, lung and pancreas transplants are performed in three (Bern, Lausanne and 
Zürich), three (Bern, Geneva and Zürich), two (Lausanne and Zürich) and two (Geneva and Zürich) 
centers, respectively. We performed an observational retrospective cohort study to describe the 
incidence, risk factors and outcomes of PJP in this multicenter cohort of SOTr. All consecutive adult 
(≥18 years) patients who received a first SOT (heart, kidney, liver, lung, pancreas, or combined) 
between 01.05.2008 and 01.05.2016 were included in this study. Patients were censored for death, 
graft loss, loss-to-follow-up, or consent withdrawal. For patients without a censoring event, a 
minimum 6-month follow-up post-SOT was required for study inclusion. Patients were excluded if 
they received pancreatic islets or small bowel or had >1 SOT during the study period.  
 
Pneumocystis prophylaxis. Although Pneumocystis-prophylaxis guidelines are not universal in 
Switzerland, prophylaxis is generally provided for 12 months to lifelong in lung recipients, 6 months 
in heart and kidney transplant recipients, and in case of severe immunosuppression for liver 
recipients. In case of rejection episodes, treatment with thymoglobulin or intensification of 
immunosuppression and/or CMV infection/disease prophylaxis is further prolonged.  
 
Data collection. Data collection was performed in a two-step approach. All patients were identified 
using the STCS database. The following data were directly retrieved from the database: (i) 
demographics (age, gender), (ii) baseline SOT variables: SOT type, transplant center, year of 
transplant, type of donor (living vs. cadaveric), induction immunosuppression, cytomegalovirus 
(CMV), Epstein-Barr virus (EBV) and toxoplasmosis donor and recipient serology status, (iii) baseline 
(at the time of SOT) comorbidities: diabetes mellitus, chronic renal insufficiency, and body-mass 
index (BMI) at the time of transplantation, (iv) maintenance immunosuppression administered for ≥7 
days and acute organ rejection during the first 6 months post-transplant, and (v) post-transplant 
complications: rejection (cellular or antibody-mediated) and CMV infection and/or disease requiring 
treatment initiation with a systemically administered CMV-active agent during the first year post-
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
SOT. Pneumocystis-prophylaxis with trimethoprim-sulfamethoxazole (TMP-SMX), atovaquone, 
dapsone, or pentamidine initiated during the first 3 months post-transplant and administered for ≥7 
days was recorded. Additional data pertaining to PJP were retrospectively extracted from hospital 
charts using a case-report form, including: (i) radiological findings, (ii) histopathology, (iii) 
microbiology, including direct microscopy, polymerase-chain reaction (PCR) and serum b-D glucan, 
and (v) administered treatment.  
 
Definitions. PJP diagnosis was based on consensus guidelines, requiring a positive direct microscopy 
by immunofluorescence on induced sputum or bronchoalveolar lavage (BAL) and/or a positive PCR 
assay on a BAL specimen (17). The day the first positive clinical sample for Pneumocystis spp. was 
obtained was considered as the day of PJP diagnosis. For the purposes of this study baseline chronic 
renal insufficiency was defined as serum creatinine ≥1.5mg/dl and/or requirement for hemodialysis. 
Primary Pneumocystis-prophylaxis was defined as any Pneumocystis-active prophylaxis initiated 
during the first 3 months post-transplant and administered for ≥7 days. Early- and late-onset PJP 
were defined as an infection diagnosed ≤ and >365 days post-transplant, respectively. CMV infection 
and disease were diagnosed based on prior published guidelines (18, 19). Due to the small number 
of cases of CMV disease, CMV infection and disease were considered together in all analyses 
performed for the purposes of this study. Acute rejection was defined for each organ following 
standard international guidelines (20). 
 
Statistical analysis. Standard descriptive statistics were used to summarize the study population 
characteristics. The Fisher’s exact or chi-square tests were used for categorical variables and 
Student’s t -test for continuous variables. Continuous variables are presented as mean, with 
standard deviation (SD) and range. Cumulative incidences of PJP among different SOT categories, 
transplant centers and year of transplantation were estimated from first day post-transplantation to 
PJP during the study period, censoring for death, graft loss, and loss of follow-up. Logistic regression 
was used to identify risk factors for PJP. Independent variables with P<0.12 in univariable analyses 
were subsequently entered in a backward stepwise fashion into a multivariable logistic regression 
model with mixed effect. Results are presented as odds ratios (OR) with 95% confidence intervals 
(CI). Collinearity among independent variables was assessed using variance inflation factors (VIFs), 
with VIF values >3 suggesting the presence of significant collinearity. The Pearson correlation 
coefficient was additionally used to determine the strength of possible correlations between 
independent variables. The overall mortality was analyzed using Kaplan-Meier survival curves. The 
log-rank test was used to compare survival distribution between groups. A two sided test was 
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performed and a P-value<0.05 was considered to be statistically significant. Data were analyzed 
using STATA 14 statistical software.  
 
Results 
Incidence. The study population of 2842 SOTr included 1667 (58.7%) kidney, 567 (20.0%) liver, 251 
(8.8%) lung, 204 (7.2%) heart, 85 (3.0%) kidney-pancreas, and 68 (2.4%) combined transplant 
recipients. Forty-one (1.4%) patients developed PJP with an overall incidence rate of 0.01/1000 
person-days (95% confidence interval (CI):  0.009, 0.02). The baseline patient characteristics are 
shown in Table 1. Incidence rates for PJP were 0.02/1000 person-days  (95% CI 0.01, 0.06) for heart, 
0.01 (95% CI 0.01, 0.02) for kidney, 0.009/1000 person-days  (95% CI 0.001, 0.07) for kidney-
pancreas, 0.006/1000 person-days  (95% CI 0.002, 0.02) for liver, and 0.004/1000 person-days  (95% 
CI 0.0005, 0.03) for lung SOTr, respectively (log-rank: 0.08) (Figure 1a and Table 2).  
 
Incidence rate was significantly higher at center-2 (0.06/1000 person-days, 95% CI 0.04, 0.09) 
compared to all other centers (0.005, 95% CI 0.003, 0.008/1000 person-days; log-rank<0.001; Figure 
1b). Notably, more than half (27/41, 65.8%) of PJP cases occurred at center-2 compared to other 
centers (14/41, 34.2%; P-value: <0.001). Fewer patients (328/395, 83.0%) at center-2 received 
Pneumocystis-prophylaxis compared to other centers (2137/2447, 87.3%; P-value: 0.02). Whereas 
administration of primary Pneumocystis-prophylaxis did not significantly change in all other centers 
during the study period (P-value: 0.64), there was an increase in the proportion of patients who 
received primary Pneumocystis-prophylaxis at center-2 from 77.2% (200/259 patients) in 2008-2012 
to 94.1% (128/136 patients) in 2012-2016 (P-value<0.001; Figure 1c). The number of PJP cases at 
center-2 dropped from 10.0% (26/259 patients) in 2008-2012 to 0.7% (1/136; P-value<0.001) in 
2013-2016, reaching the level of other centers (Figures 1c and d).   
 
Pneumocystis prophylaxis. The vast majority (2465, 86.7%) of SOTr received primary Pneumocystis-
prophylaxis for a mean duration of 316 days (SD: 526, median: 176 days, range 0, 5944). Primary 
Pneumocystis-prophylaxis was not administered in 377 (13.3%) patients: 7 (1.8%) combined, 35 
(9.3%) heart, 112 (29.7%) kidney, 4 (1.1%) kidney-pancreas, 213 (56.5%) liver, and 6 (1.6%) lung 
transplant recipients. PJP occurred more frequently among them (12/377, 3.2%) compared to SOTr 
who received Pneumocystis-prophylaxis (29/2465, 1.2%; P-value=0.002). PJP incidence rate was 
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0.01/1000 person-days (95% CI 0.007, 0.01) in patients with and 0.03/1000 person-days (95% CI: 
0.02, 0.05) in patients without primary Pneumocystis-prophylaxis (log-rank<0.001: Figure 2a). PJP 
was an early event, with most events occurring during the six months following SOT in the majority 
of SOTr who did not receive primary Pneumocystis-prophylaxis and developed PJP (10/12, 83.3%), 
compared to those patients who received prophylaxis (11/29, 37.9%; P-value: 0.008; Figure 2b). 
Among patients with late-onset PJP, most cases (13/20, 65%) were observed during the 2nd year 
post-transplant. There were no breakthrough PJP cases during administration of Pneumocystis-
prophylaxis.  
 
Duration of prophylaxis was longer in lung (mean: 1117 days, SD: 52, 95% CI 1015, 1218) compared 
to other SOTr (mean: 238, SD: 8, 95% CI 222, 254; P-value<0.001; Figure 2c). Mean duration of 
primary Pneumocystis-prophylaxis was 671 days (SD: 716, median: 376, range: 0, 3791) in heart 
transplant recipients, 226 days (SD: 373, median: 177, range: 0, 5444) in kidney and 117 days (SD: 
279, median: 65, range: 0, 3410) in liver transplant recipients, respectively. Prophylaxis was stopped 
in the vast majority of kidney (943/1655, 57%) and liver (482/563, 85.6%) transplant recipients by 6-
months post-transplant. By 1-year post-transplant, prophylaxis was stopped in almost all recipients 
of a combined, kidney, kidney-pancreas and liver transplant. In contrast, more than half of heart 
(105/199, 52.8%) and lung (191/251, 76.1%) transplant recipients remained on prophylaxis by 1-year 
post-transplant (log-rank<0.001; Figure 2d).  
 
Timing, Diagnosis and Treatment of PJP (Table 2). PJP occurred at a mean of 493 days (SD: 438, 
median: 363, range: 67, 1915) post-transplant. Twenty-one (of 41, 51.2%) cases of PJP occurred 
during the 1st year post-transplant vs 20 (48.8%) thereafter. Induced sputum and BAL specimens 
were obtained in 4 (9.8%) and 37 (90.2%) patients, respectively. Histopathology was performed in 
only 3 (7.3%) patients. Direct microscopy by immunofluorescence was positive in 37 (of 41, 90.2%) 
patients. A PCR was performed and found positive in 8 (of 41, 19.5%) patients: 4 (of 8, 50%) patients 
were diagnosed based on a positive PCR result only and 4 (50%) patients had a concomitant positive 
immunofluorescence test (one patient had a histopathology positive result as well). A total of 34 
(82.9%) patients had a chest-computed tomography (CT) performed and 8 (19.5%) patients 
underwent a chest XR for the diagnosis of PJP. Ground-glass opacities were the most frequently 
identified radiologic finding (29, 70.7%), followed by non-specific infiltrates (17, 41.5%), nodular 
lesions (11, 26.8%) and pleural effusions (4, 9.8%). Among 35 patients with known absolute 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
lymphocyte count (ALC) within 7 days of PJP diagnosis, the mean ALC was 548 cells/mm3 (SD: 411, 
median: 440, range: 50, 1930). The vast majority of patients (35, 85.4%) were treated with TMP-
SMX, followed by clindamycine-primaquine (5, 12.2%) and pentamidine (1, 2.4%). Treatment was 
changed in 14 (34.2%) patients: in 11 (of 14, 78.6%) patients from intravenous to orally administered 
TMP-SMX and in 3 (21.4%) patients from TMP-SMX to another agent. Treatment duration was at a 
mean of 20.6 days (SD: 5.1, median: 21 days, range 5, 34). Twenty-five (of 34 with available data, 
73.5%) patients received concomitant treatment with corticosteroids for a mean duration of 26.3 
days (SD: 20.1, median: 21 days, range: 10, 90).   
 
Risk factor analysis for PJP. Multivariable analyses on the overall patient population identified 
transplantation at center-2 (OR: 11.0, 95% CI 4.6, 26.1, P-value<0.001) and kidney transplant (OR: 
3.5, 95% CI 1.3, 9.3, P-value: 0.01) as significant risk factors for PJP (Table 3). Transplantation during 
2013-2016 (OR: 0.14, 95% CI 0.03, 0.6, P-value: 0.008) was protective for PJP. There was no 
significant collinearity between independent variables, with a mean VIF=1.0. However, the Pearson 
correlation coefficient identified possible associations between (i) SOT-type and: age (r=0.11, P-
value<0.001), SOT-center (r=0.10, P-value<0.001), mTOR-inhibitor administration (r=-0.18, P-
value<0.001), and Pneumocystis-prophylaxis (r=0.23, P-value<0.001), and (ii) SOT-center and mTOR-
inhibitor administration (r=0.19, P-value<0.001). In addition, administration of primary PJP 
prophylaxis (particularly for center 2) changed during the study period. Hence, another model was 
created excluding SOT-center, SOT-type and SOT-year. In this model, age ≥65 year was a significant 
predictor for PJP (OR: 2.4, 95% CI 1.1, 5.5, P-value 0.03), followed by CMV infection/disease (OR: 2.5, 
95% CI 1.2, 5.4, P-value 0.006). Administration of primary Pneumocystis-prophylaxis (OR: 0.3, 95% CI 
0.14, 0.7, P-value: 0.006) was protective for PJP. 
 
Considering the significantly more cases of PJP at center-2, separate risk factor analyses were 
performed for all other centers after excluding center-2 and for center-2 alone (Table 4). When 
patients from center-2 were excluded, there was a trend for age ≥65 year (OR: 2.9, 95%CI 0.9, 1.1, P-
value: 0.07) and rejection episode during the first 6 months post-transplant (OR: 2.7, 95%CI 0.9, 7.8, 
P-value: 0.07) to be PJP predictors in multivariable analyses. Univariable analyses performed on 
patients enrolled at center-2 alone revealed age ≥65 year and a kidney transplant as significant PJP 
predictors, while an SOT during 2013-2016 and administration of Pneumocystis-prophylaxis during 
the first 3 months post-transplant appeared to be protective. In multivariable analyses, a kidney 
transplant (OR: 5.6, 95%CI 2.1, 15.1, P-value: 0.001) was the most significant PJP predictor, while 
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transplantation in 2013-2016 was protective (OR: 0.08, 95%CI 0.01, 0.6, P-value: 0.02). Considering 
the lack of Pneumocystis-prophylaxis administration during the first part of the study (2008-2012) at 
center-2, mainly observed in kidney SOTr, SOT type and time were subsequently removed from the 
model. In these repeat analyses (multivariable analysis-II), only age ≥65 year (OR: 2.4, 95%CI 1.0. 5.6, 
P-value: 0.05) remained a significant PJP predictor, while administration of primary Pneumocystis-
prophylaxis was protective for PJP (OR: 0.4, 95%CI 0.17, 0.9, P-value: 0.04).  
 
Outcomes. Two (of 41, 4.9%) patients with PJP died by 12-weeks post-PJP diagnosis, with 1-year 
overall mortality of 14.6% (6/41 patients). One patient died during treatment for PJP with 
uncontrolled infection, while the other patient died after completion of PJP treatment, without 
evidence of active infection at the time of death. Overall, 11 (of 41, 26.8%) patients with PJP vs 443 
(of 2801, 15.8%) patients without PJP (log-rank: 0.36) were dead at the end of the study-follow-up. 
Survival did not significantly differ between centers (log-rank: 0.17) or year of transplantation (log-
rank: 0.32). Investigation of mortality predictors among the 41 SOTr with PJP failed to identify any 
significant associations between independent variables (including antibiotic treatment type and 
duration or administration of corticosteroids) and survival in univariable analyses (data not shown). 
 
Discussion 
In this large multi-center 8-year cohort of SOTr between 2008 and 2016 PJP remains a relatively rare 
event post-transplant with a wide time-distribution, depending on the administration of primary 
Pneumocystis-prophylaxis.  
 
Effective prophylaxis has significantly decreased the incidence of PJP in SOTr from 5-15% to 0.3-2.5% 
(1, 3, 6, 7, 9, 15). We report an overall incidence rate of 0.01/1000 person-days for PJP in a cohort of 
almost 3000 SOTr with a mean follow-up time of 3 years. This set of data from the 2000-2010’s 
confirm that PJP has become a rare event post-SOT, mostly due to administration of effective 
prophylaxis. Indeed, our data provide a “snapshot” of current primary Pneumocystis-prophylaxis 
administration practices and its effects. More than 85% of patients in this cohort received primary 
Pneumocystis-prophylaxis for variable duration. Consistent with current recommendations, 
administration of prophylaxis was longer for heart and lung transplant recipients and discontinued in 
>90% of non-cardiothoracic SOTr by 1-year post-transplant (3, 5, 6, 21). Among SOTr who received 
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primary Pneumocystis-prophylaxis most cases were observed after the 1st year post-transplant, 
predominately clustering during the 2nd year post-transplant after prophylaxis was discontinued. A 
similar shift in the timing of PJP in SOTr from the 1st to the 2nd year post-transplant has been recently 
described by Iriart et al and been attributed to administration of effective early-post-transplant 
Pneumocystis-prophylaxis (2, 3). Furthermore, multivariable analyses identified transplantation in 
the first part of the study-period (2008-2012) as a significant predictor for PJP. Hence, the longer 
SOTr are alive post-transplant the higher the likelihood they may develop PJP. Further studies are 
required to identify risk factors that may help stratify SOTr in need for prolongation or re-institution 
of Pneumocystis-prophylaxis later post-transplant (2, 3, 15). 
 
Lack or inconsistent administration of Pneumocystis-prophylaxis have been, prior, associated with 
high rates of PJP (22-29). Almost 15% of SOTr in this cohort did not receive Pneumocystis-
prophylaxis. Significantly higher rates of PJP occurring predominately during the 1st year post-
transplant were observed in this patient-group. The importance of Pneumocystis-prophylaxis was 
nicely illustrated in the case of center-2. During the first part of the study-period, PJP incidence was 
significantly higher at that center, where primary prophylaxis was not routinely administered. When 
prophylactic strategies changed to include >90% of SOTr, the incidence of PJP at center-2 rapidly 
dropped to the level of other centers. In an era, during which PJP-prophylaxis has become the 
standard of care, these data represent a valuable reminder of the importance of timely 
administration of effective Pneumocystis-prophylaxis in SOTr. Indeed, primary Pneumocystis-
prophylaxis was identified as a protective factor against PJP in multivariable analyses, specifically for 
center-2 (Table 4).  
 
Consistent with prior reports, older age (particularly ≥65 year-old patients) emerged as a significant 
risk factor for PJP (2, 3, 6, 30). As previously described, CMV infection/disease was also identified as 
an independent predictor of PJP in multivariable analyses on the overall study population (2, 3, 6, 7). 
However, the effect of CMV infection/disease on PJP was diluted in the separate analyses performed 
based on different SOT-centers (Table 4). There was a trend for administration of mTOR-inhibitors as 
maintenance immunosuppression during the first 6 months post-transplant as a predictor of PJP. A 
probable association between administration of sirolimus and infectious complications, including 
PJP, has been previously described (10, 30-33). This may, in part, be attributed to the impact of 
mTOR inhibition on T- and B-cell immunity (34, 35). Moreover, a recently published meta-analysis 
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suggested that administration of sirolimus may be associated with higher mortality rates due to 
infections in kidney transplant recipients (36). Although intriguing, these observations need to be 
further investigated to make any more meaningful conclusions. Lymphopenia has been previously 
identified as a significant predictor of PJP among SOTr (3, 10). Most SOTr with PJP in this cohort had 
an ALC<500 cells/mL. Iriart et al have suggested that the triad of age ≥65 years, 2nd year post-
transplant, and lymphopenia could potentially identify patients at higher risk for PJP (3). Similarly, 
our observations suggest that high clinical suspicion for PJP could be applied in ≥65 year-old 
lymphopenic SOTr -treated with mTOR-inhibitors, who present with a syndrome compatible with 
PJP, particularly during the 2nd year post-transplant. 
  
Considering the lower organism burden in HIV-negative patients with PJP, current guidelines 
recommend shorter treatment courses for SOTr with PJP (14-21 days) (4, 37). Most patients in this 
cohort received treatment with TMP-SMX for a duration of 21 days and co-administration of 
corticosteroids. As PJP has become a rare complication in SOTr, it is very unlikely that prospective, 
randomized clinical trials on the treatment of PJP in this patient population will be performed. Our 
data provide an update on real-life management of PJP in SOTr, suggesting that clinicians are more 
likely to use longer treatment courses and corticosteroids to treat SOTr with PJP. In contrast to 
previously reported high mortality rates (27–60%) in HIV-negative immunocompromised patients 
with PJP, 1-year mortality was <15% in this cohort (2, 4, 33, 38). This may reflect the progress 
attained in the field of PJP diagnosis, with the routine use of PCR and b-D-glucan at most centers, 
leading to earlier diagnosis and timely treatment initiation. In a small number of cases the diagnosis 
of PJP was solely based on PCR, with the potential for over-diagnosis of colonization. However, their 
treating physicians were convinced enough to treat these patients with full-courses of antibiotic 
treatment, frequently co-administered with corticosteroids.  
 
Notably, one of the major limitations of the study was that the PCR cycle threshold (Ct) was not 
available for cases diagnosed based on a positive PCR, although only 4 cases were diagnosed based 
on a positive Pneumocystis PCR only. Finally, we were not able to exclude a possible outbreak at 
center-2, as molecular typing was performed but due to fragmented DNA results were non-
interpretable. In conclusion, in the Pneumocystis-prophylaxis era PJP appears to be a rare, albeit 
associated with favorable outcomes, post-transplant complication, with most cases occurring post-
discontinuation of PJP prophylaxis particularly during the 2nd year post-transplant in older patients 
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with lymphopenia. Additional research may help us identify indications for prolongation or 
reinstitution of Pneumocystis-prophylaxis later post-transplant in specific patient categories.  
 
References 
1. Fillatre P, Decaux O, Jouneau S, Revest M, Gacouin A, Robert-Gangneux F, et al. Incidence 
of Pneumocystis jiroveci pneumonia among groups at risk in HIV-negative patients. Am J Med. 
2014;127(12):1242 e11-7. 
2. Iriart X, Bouar ML, Kamar N, Berry A. Pneumocystis Pneumonia in Solid-Organ 
Transplant Recipients. J Fungi (Basel). 2015;1(3):293-331. 
3. Iriart X, Challan Belval T, Fillaux J, Esposito L, Lavergne RA, Cardeau-Desangles I, et al. 
Risk factors of Pneumocystis pneumonia in solid organ recipients in the era of the common use 
of posttransplantation prophylaxis. Am J Transplant. 2015;15(1):190-9. 
4. Martin SI, Fishman JA, Practice ASTIDCo. Pneumocystis pneumonia in solid organ 
transplantation. Am J Transplant. 2013;13 Suppl 4:272-9. 
5. Muhlethaler K, Bogli-Stuber K, Wasmer S, von Garnier C, Dumont P, Rauch A, et al. 
Quantitative PCR to diagnose Pneumocystis pneumonia in immunocompromised non-HIV 
patients. The European respiratory journal. 2012;39(4):971-8. 
6. de Boer MG, Kroon FP, le Cessie S, de Fijter JW, van Dissel JT. Risk factors for 
Pneumocystis jirovecii pneumonia in kidney transplant recipients and appraisal of strategies for 
selective use of chemoprophylaxis. Transpl Infect Dis. 2011;13(6):559-69. 
7. Wang EH, Partovi N, Levy RD, Shapiro RJ, Yoshida EM, Greanya ED. Pneumocystis 
pneumonia in solid organ transplant recipients: not yet an infection of the past. Transpl Infect 
Dis. 2012;14(5):519-25. 
8. Fishman JA. Prevention of infection caused by Pneumocystis carinii in transplant 
recipients. Clin Infect Dis. 2001;33(8):1397-405. 
9. Anand S, Samaniego M, Kaul DR. Pneumocystis jirovecii pneumonia is rare in renal 
transplant recipients receiving only one month of prophylaxis. Transpl Infect Dis. 
2011;13(6):570-4. 
10. De Castro N, Xu F, Porcher R, Pavie J, Molina JM, Peraldi MN. Pneumocystis jirovecii 
pneumonia in renal transplant recipients occurring after discontinuation of prophylaxis: a case-
control study. Clin Microbiol Infect. 2010;16(9):1375-7. 
11. Kasiske BL, Zeier MG, Chapman JR, Craig JC, Ekberg H, Garvey CA, et al. KDIGO clinical 
practice guideline for the care of kidney transplant recipients: a summary. Kidney international. 
2010;77(4):299-311. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
12. Transplantation EEGoR. European best practice guidelines for renal transplantation. 
Section IV: Long-term management of the transplant recipient. IV.7.1 Late infections. 
Pneumocystis carinii pneumonia. Nephrol Dial Transplant. 2002;17 Suppl 4:36-9. 
13. Gordon SM, LaRosa SP, Kalmadi S, Arroliga AC, Avery RK, Truesdell-LaRosa L, et al. 
Should prophylaxis for Pneumocystis carinii pneumonia in solid organ transplant recipients 
ever be discontinued? Clin Infect Dis. 1999;28(2):240-6. 
14. Green H, Paul M, Vidal L, Leibovici L. Prophylaxis for Pneumocystis pneumonia (PCP) in 
non-HIV immunocompromised patients. The Cochrane database of systematic reviews. 
2007(3):CD005590. 
15. Borstnar S, Lindic J, Tomazic J, Kandus A, Pikelj A, Prah J, et al. Pneumocystis jirovecii 
pneumonia in renal transplant recipients: a national center experience. Transplant Proc. 
2013;45(4):1614-7. 
16. Koller MT, van Delden C, Muller NJ, Baumann P, Lovis C, Marti HP, et al. Design and 
methodology of the Swiss Transplant Cohort Study (STCS): a comprehensive prospective 
nationwide long-term follow-up cohort. Eur J Epidemiol. 2013;28(4):347-55. 
17. Alanio A, Hauser PM, Lagrou K, Melchers WJ, Helweg-Larsen J, Matos O, et al. ECIL 
guidelines for the diagnosis of Pneumocystis jirovecii pneumonia in patients with 
haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother. 
2016;71(9):2386-96. 
18. Humar A, Michaels M, Monitoring AIWGoID. American Society of Transplantation 
recommendations for screening, monitoring and reporting of infectious complications in 
immunosuppression trials in recipients of organ transplantation. Am J Transplant. 
2006;6(2):262-74. 
19. Ljungman P, Boeckh M, Hirsch HH, Josephson F, Lundgren J, Nichols G, et al. Definitions 
of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials. Clin 
Infect Dis. 2017;64(1):87-91. 
20. Golshayan D, Wojtowicz A, Bibert S, Pyndiah N, Manuel O, Binet I, et al. Polymorphisms 
in the lectin pathway of complement activation influence the incidence of acute rejection and 
graft outcome after kidney transplantation. Kidney international. 2016;89(4):927-38. 
21. Pliquett RU, Asbe-Vollkopf A, Hauser PM, Presti LL, Hunfeld KP, Berger A, et al. A 
Pneumocystis jirovecii pneumonia outbreak in a single kidney-transplant center: role of 
cytomegalovirus co-infection. Eur J Clin Microbiol Infect Dis. 2012;31(9):2429-37. 
22. Sassi M, Ripamonti C, Mueller NJ, Yazaki H, Kutty G, Ma L, et al. Outbreaks of 
Pneumocystis pneumonia in 2 renal transplant centers linked to a single strain of Pneumocystis: 
implications for transmission and virulence. Clin Infect Dis. 2012;54(10):1437-44. 
23. Arend SM, Westendorp RG, Kroon FP, van't Wout JW, Vandenbroucke JP, van Es LA, et al. 
Rejection treatment and cytomegalovirus infection as risk factors for Pneumocystis carinii 
pneumonia in renal transplant recipients. Clin Infect Dis. 1996;22(6):920-5. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
24. Branten AJ, Beckers PJ, Tiggeler RG, Hoitsma AJ. Pneumocystis carinii pneumonia in 
renal transplant recipients. Nephrol Dial Transplant. 1995;10(7):1194-7. 
25. Dummer JS. Pneumocystis carinii infections in transplant recipients. Seminars in 
respiratory infections. 1990;5(1):50-7. 
26. Elinder CG, Andersson J, Bolinder G, Tyden G. Effectiveness of low-dose cotrimoxazole 
prophylaxis against Pneumocystis carinii pneumonia after renal and/or pancreas 
transplantation. Transpl Int. 1992;5(2):81-4. 
27. Hardy AM, Wajszczuk CP, Suffredini AF, Hakala TR, Ho M. Pneumocystis carinii 
pneumonia in renal-transplant recipients treated with cyclosporine and steroids. J Infect Dis. 
1984;149(2):143-7. 
28. Hennequin C, Page B, Roux P, Legendre C, Kreis H. Outbreak of Pneumocystis carinii 
pneumonia in a renal transplant unit. Eur J Clin Microbiol Infect Dis. 1995;14(2):122-6. 
29. Lufft V, Kliem V, Behrend M, Pichlmayr R, Koch KM, Brunkhorst R. Incidence of 
Pneumocystis carinii pneumonia after renal transplantation. Impact of immunosuppression. 
Transplantation. 1996;62(3):421-3. 
30. Neff RT, Jindal RM, Yoo DY, Hurst FP, Agodoa LY, Abbott KC. Analysis of USRDS: 
incidence and risk factors for Pneumocystis jiroveci pneumonia. Transplantation. 
2009;88(1):135-41. 
31. Dominguez J, Mahalati K, Kiberd B, McAlister VC, MacDonald AS. Conversion to 
rapamycin immunosuppression in renal transplant recipients: report of an initial experience. 
Transplantation. 2000;70(8):1244-7. 
32. Kahan BD, Wong RL, Carter C, Katz SH, Von Fellenberg J, Van Buren CT, et al. A phase I 
study of a 4-week course of SDZ-RAD (RAD) quiescent cyclosporine-prednisone-treated renal 
transplant recipients. Transplantation. 1999;68(8):1100-6. 
33. Eitner F, Hauser IA, Rettkowski O, Rath T, Lopau K, Pliquett RU, et al. Risk factors for 
Pneumocystis jiroveci pneumonia (PcP) in renal transplant recipients. Nephrol Dial Transplant. 
2011;26(6):2013-7. 
34. Eiden AM, Zhang S, Gary JM, Simmons JK, Mock BA. Molecular Pathways: Increased 
Susceptibility to Infection Is a Complication of mTOR Inhibitor Use in Cancer Therapy. Clin 
Cancer Res. 2016;22(2):277-83. 
35. Yang H, Wang X, Zhang Y, Liu H, Liao J, Shao K, et al. Modulation of TSC-mTOR signaling 
on immune cells in immunity and autoimmunity. J Cell Physiol. 2014;229(1):17-26. 
36. Knoll GA, Kokolo MB, Mallick R, Beck A, Buenaventura CD, Ducharme R, et al. Effect of 
sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-
analysis of individual patient data. BMJ. 2014;349:g6679. 
37. Kovacs JA, Hiemenz JW, Macher AM, Stover D, Murray HW, Shelhamer J, et al. 
Pneumocystis carinii pneumonia: a comparison between patients with the acquired 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med. 
1984;100(5):663-71. 
38. Roux A, Canet E, Valade S, Gangneux-Robert F, Hamane S, Lafabrie A, et al. Pneumocystis 
jirovecii pneumonia in patients with or without AIDS, France. Emerg Infect Dis. 
2014;20(9):1490-7. 
 
Figure legends 
Figure 1. Incidence of Pneumocystis jirovecii pneumonia (PJP).  
 
(a) PJP incidence based on the type of transplanted organ, log-rank: 0.08 between kidney and other 
SOT. (b) PJP incidence between center-2 and other transplant centers, log-rank<0.001. (c) Proportion 
of patients who received Pneumocystis prophylaxis by year of transplantation between center-2 and 
other centers. (d) Incidence of PJP at center-2 among patients transplanted between 2008 and 2012 
compared to patients at the same center transplanted in 2013-2016 and other centers (log-
rank<0.001).  
 
Figure 2. Administration of Pneumocystis prophylaxis.  
 
(a) Overall incidence of Pneumocystis jirovecii pneumonia (PJP) among 377 patients who did not 
receive primary Pneumocystis-prophylaxis (incidence rate 0.003%) compared to those who did 
(incidence rate 0.001%; log-rank<0.001). (b) One-year post-transplant incidence of PJP between 
patients who did and those who did not receive Pneumocystis-prophylaxis (log-rank<0.001). (c) 
Duration of Pneumocystis-prophylaxis based on the type of transplanted organ presented as box-
plots. (d) Duration of Pneumocystis-prophylaxis during the first year post-transplant among different 
organ types.  
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Table 1. Baseline patient characteristics.  
 
 PJP
N: 41 (%) 
No PJP
N: 2801 (%) 
Demographics   
Age, Mean Years (SD; Range) 56.9 (12.1; 18.9-76.9) 52.2 (13.1; 18, 80.7) 
Gender, Female 17 (41.5) 994 (35.5) 
Transplant Characteristics   
SOT type   
Combined 0 68 (2.4)
Heart 5 (12.2) 199 (7.1)
Kidney 30 (73.2) 1637 (58.4)
Kidney-Pancreas 1 (2.4) 84 (3.0) 
Liver 4 (9.8) 563 (20.1) 
Lung 1 (2.4) 250 (8.9) 
SOT center   
Center 1 2 (4.9) 452 (16.1) 
Center 2 27 (65.8) 368 (13.1) 
Center 3 2 (4.9) 418 (14.9) 
Center 4 2 (4.9) 496 (17.7) 
Center 5 2 (4.9) 139 (5.0) 
Center 6 6 (14.6) 928 (33.1) 
SOT year   
2008 6 (14.3) 263 (9.4)
2009 11 (26.8) 384 (13.7)
2010 7 (17.1) 406 (14.5)
2011 9 (21.5) 397 (14.2)
2012 5 (12.9) 365 (13.0) 
2013 2 (4.9) 368 (13.1) 
2014 1 (2.4) 354 (12.6) 
2015 0 224 (8.0) 
2016 0 40 (1.4) 
Donor type   
Dead  30 (73.2) 1969 (70.3) 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Living  11 (26.8) 746 (26.6) 
NHBD 0 86 (3.1) 
Induction Immunosuppression1   
Thymoglobulin 6 (14.6) 688 (24.6) 
Basiliximab/Daclizumab 41 (75.6) 1914 (68.3) 
IVIG 0 169 (6.0) 
Rituximab 2 (4.8) 111 (4.0) 
Maintenance Immunosuppression2 
Calcineurin Inhibitor  40 (97.6) 2727 (97.4)
Mycophenolate Mofetil 40 (97.6) 2648 (94.5)
mTOR-inhibitor 8 (19.5) 231 (8.3)
Steroids 41 (100) 2637 (94.1) 
Serologies   
CMV, D+R-3 9 (21.9) 533 (19.2) 
EBV, D+R-4 0 120 (4.4) 
Toxoplasmosis, D+R-5 2 (7.4) 497 (23.3) 
Comorbidities at Time of SOT   
Diabetes Mellitus 10 (24.4) 534 (19.1) 
Chronic Renal Insufficiency 25 (61.0) 1845 (65.9) 
Body Mass Index, Mean (SD; Range) 25.7 (4.8; 18.2, 36.2) 24.8 (9.2; 14.1, 35.7) 
Pneumocystis Prophylaxis   
First 3 months for >7 days 29 (70.7) 2436 (87.0)
Duration of Prophylaxis, Mean Days (SD; Range) 245 (372; 123, 367) 317 (528 ; 297, 336)
 
PJP: Pneumocystis jirovecii pneumonia, SD: Standard Deviation, SOT: Solid Organ Transplant, NHBD: Non-heart beating 
donor, IVIG: Intravenous Immunoglobulin, CMV: Cytomegalovirus, D: Donor, R: Recipient, EBV: Epstein-Barr Virus. 
 
1 Induction immunosuppression agents were not mutually exclusive. One patient might have received more than 1 agents. 
2 Maintenance immunosuppression agents were not mutually exclusive. One patient might have received more than 1 
agents. Only agents administered for >7 days during the first 6 months post-transplant are reported. 
3 CMV D/R status was available for 41 and 2779 patients with and without PJP. 
4 EBV D/R status was available for 40 and 2744 patients with and without PJP. 
5 Toxoplasmosis D/R status was available for 27 and 2135 patients with and without PJP.  
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Table 2. Characteristics of patients with Pneumocystis jirovecii pneumonia. 
 
 
 Heart
N=5 (%) 
Kidney
N=30 (%) 
Kidney-
Pancreas 
N=1 
Liver 
N=4 (%) 
Lung 
N=1 
Demographics      
Age, Mean Years (SD; Range) 54.7 (6.4 ; 
49.8, 65.6) 
59.4 (11.8 ; 
22, 75) 
43.2 63.2 (8.5 ; 51.6, 
70) 
40.3 
Gender, Female 3 (60) 12 (40) 0 1 (25) 1 
SOT center   
Center 1 0 2 (6.7) 0 1 (25) 0 
Center 2 4 (80) 22 (73.3) 0 0 0 
Center 3 0 1 (3.3) 0 1 (25) 0 
Center 4 0 0 0 1 (25) 1 
Center 5 0 2 (6.7) 0 0 0 
Center 6 1 (20) 3 (10) 1 1 (25) 0 
SOT year, 2008-2012 5 (100) 27 (90) 1 4 (100) 1 
2008 1 3 1 0 1 
2009 1 9 0 1 0 
2010 1 6 0 0 0 
2011 2 5 0 2 0 
2012 0 4 0 1 0 
2013 0 2 0 0 0 
2014 0 1 0 0 0 
2015 0 0 0 0 0 
2016 0 0 0 0 0 
Pneumocystis Primary Prophylaxis 3 (60) 21 (70) 1 3 (75) 1 
Duration of Primary Prophylaxis, 
Mean Days (SD; Range) 
555 (726 ; 0, 
1745) 
149 (160 ; 0, 
725) 
179 95.7 (106 ; 0, 
235) 
1495 
PJP Incidence 0.002% 0.001% 0.001% 0.0006% 0.0004% 
PJP Diagnosis      
Timing post-SOT, Mean Days (SD; 
Range) 
407 (316 ; 67, 
844) 
527 (469 ; 80, 
1915) 
240 440 (499 ; 71, 
1163) 
363 
Early PJP 2 (40) 8 (26.7) 0 2 (50) 0 
Specimen      
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Sputum 0 3 (10) 1 0 1 
BAL 5 (100) 27 (90) 0 4 (100) 0 
Microbiology   
Direct microscopy 5 (100) 26 (100) 1 4 (100) 1 
PCR 0 6 (20.0) 0 1 (25.0) 1 
Histopathology, Done 1 (100) 0 0 2 (100) 0 
Positive 0 0 0 2 (100) 0 
Radiology      
Chest CT 4 (80) 26 (86.7) 1 3 (75.0) 0 
Chest Radiography 1 (20) 4 (13.3) 1 1 (25.0) 1 
Radiolographic Findings      
Ground-Glass Opacities 3 (60) 23 (76.7) 0 3 (75.0) 0 
Nodular lesions 2 (40.0) 9 (30.0) 0 0 0 
Infiltrates 1 (20.0) 14 (46.7) 0 2 (50.0) 0 
Pleural effusion 1 (20.0) 2 (6.7) 0 1 (25.0) 0 
Laboratory Fndings   
WBC, x109 cells/mm3, Mean (SD; 
Range) 
3.7 (5.5 ; 2.2, 
7.4) 
7.8 (4.1 ; 2.4, 
19.6) 
13.9 5.5 (3.3 ; 3, 9.2) 3.8 
ALC cells/mm3, Mean (SD; Range) 252.5 (220 ; 
70, 570) 
520 (308 ; 50, 
1240) 
1930 742.5 (521 ; 310, 
1500) 
270 
 
SD: Standard Deviation, SOT: Solid Organ Transplant, PJP: Pneumocystis jirovecii pneumonia, IF: Immunofluorescence, BAL: 
Bronchoalveolar Lavage, PCR: Polymerase Chain Reaction, CT: Computed Tomography, WBC: White Blood Count, ALC: 
Absolute Lymphocyte Count 
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Table 3. Univariable and multivariable risk factor analyses for Pneumocystis jirovecii pneumonia.  
 
 Univariable analysis Multivariable analysis-I* Multivariable analysis-II* 
 OR 95%CI P OR 95%CI P OR 95%CI P 
Demographics          
Age  1.03 1, 1.06 0.03 Not applicable Not applicable 
Age groups, ≥65 vs <65 Years 2.6 1.3, 5.0 0.004 2.1 0.9, 5.0 0.10 2.4 1.1, 5.5 0.03
Gender, Male vs Female 1.3 0.7, 2.4 0.43   
Transplant-Associated     
SOT-type, Kidney vs other 1.9 0.9, 3.9 0.06 3.5 1.3, 9.3 0.01 Not applicable 
SOT-center, 2 vs other 12.7 6.6, 23 <0.001 11.0 4.6, 26 <0.001 Not applicable 
SOT-year, 2013-16 vs 2008-12 0.14 0.04, 0.5 0.001 0.14 0.03, 0.6 0.008 Not applicable 
Induction IS          
Thymoglobulin 0.5 0.2, 1.3 0.15       
Basiliximab 1.4 0.7, 2.9 0.32       
Rituximab 1.2 0.3, 5.2 0.77       
Maintenance IS          
Calcineurin Inhibitors 1.2 0.1, 8.0 0.94       
Mycophenolate Mofetil 2.3 0.3, 17 0.41       
mTOR-inhibitors 2.7 1.2, 6.0 0.01 2.1 0.7, 6.9 0.2 2.5 0.9, 6.9 0.07 
Steroids 1    
Post-transplant complications     
Rejection1 1.5 0.8, 3.0 0.21   
CMV infection/disease1 2.6 1.4, 4.9 0.002 1.7 0.8, 3.8 0.2 2.5 1.2, 5.4 0.006 
Serologies          
CMV, D+R- vs other 1.2 0.5, 2.0 0.66       
Toxoplasmosis, D+R- vs other 0.26 0.1, 1.1 0.07 0.3 0.07, 1.4 0.12 0.3 0.06, 1.2 0.08 
Comorbidities at SOT          
Diabetes Mellitus 1.4 0.7, 2.8 0.39       
Chronic Renal Insufficiency 0.8 0.4, 1.5 0.51       
BMI at SOT 1.0 0.9, 1.1 0.60       
Primary Pneumocystis-prophylaxis 0.36 0.2, 0.7 0.003 0.51 0.2, 1.2 0.14 0.3 0.14, 0.7 0.006 
 
OR: Odds Ratio, 95% CI: 95% Confidence Interval, P: P-value, SOT: Solid Organ Transplant, IS: Immunosuppression, CMV: 
Cytomegalovirus, D: Donor, R: Recipient, BMI: Body Mass Index.  
 
1 Rejection included the first episode of any type of acute rejection (cell- or antibody-mediated) and CMV infection/disease 
that required treatment during the first year post-transplant.  
* The Pearson correlation coefficient identified possible correlations between (i) SOT-type and: age (r=0.11, P-value<0.001), 
SOT-center (r=0.10, P-value<0.001), mTOR-inhibitors (r=0.18, P-value<0.001), CMV infection/disease (r=0.11, P-
value<0.001) and Pneumocystis-prophylaxis (r=0.23, P-value<0.001) and (ii) SOT-center and mTOR-inhibitor administration 
(r=0.19, P-value<0.001). In addition, administration of primary PJP prophylaxis (particularly for Center 2) changed during 
the study period. Hence, model-II was constructed, after excluding SOT-center, SOT-year, and SOT-type from independent 
variables. 
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Table 4. Univariable and multivariable risk factor analyses for Pneumocystis jirovecii pneumonia in: 
(i) All centers, excluding center-2, and (ii) for center-2.  
 
 All centers, excluding center-2 Center-2 
 Univariable 
analysis 
Multivariable 
analysis 
Univariable 
analysis 
Multivariable 
analysis-I2 
Multivariable 
analysis-II2 
 O
R 
95%
CI 
P O
R 
95%
CI 
P OR 95%
CI 
P OR 95%
CI 
P O
R 
95%
CI 
P 
Demographics                
Age  1.
0 
0.9, 
1.1 
0.2
5 
Not applicable 1.0 0.9, 
1.1 
0.07 Not applicable    
Age groups, 
≥65 vs <65 
Years 
2.
8 
0.9, 
8.3 
0.0
7 
2.
9 
0.9, 
8.9 
0.0
6 
2.6 1.1, 
6.0 
0.03 2.3 0.9, 
5.6 
0.07 2.
4 
1.0, 
5.6 
0.0
5 
Gender, Male 
vs Female 
1.
3 
0.5, 
24.0 
0.5
5 
   1.1 0.5, 
2.5 
0.74       
Transplant-
Associated 
               
SOT-type, 
Kidney vs 
other 
0.
9 
0.3, 
2.5 
0.8
0 
   5.6 2.1, 
15.1 
0.00
1 
5.6 2.0, 
15.3 
0.00
1 
   
SOT-year, 
2013-16 vs 
2008-12 
0.
3 
0.07, 
1.4 
0.1
3 
   0.0
7 
0.00
8, 
0.5 
0.00
8 
0.0
8 
0.01, 
0.6 
0.02    
Induction IS          
Thymoglobulin 0.
5 
0.1, 
2.2 
0.3
4 
  0.8
6 
0.3, 
2.6 
0.78     
Basiliximab 0.
9 
0.3, 
2.7 
0.8
8 
   0.9 0.3, 
2.5 
0.88       
Rituximab 1.
6 
0.2, 
12.6 
0.6
4 
   7.0 0.6, 
80.2 
0.12       
Maintenance 
IS 
               
Calcineurin 
Inhibitors 
1      1.4 0.2, 
11.0 
0.74       
Mycophenolat
e Mofetil 
0.
7 
0.09, 
5.5 
0.7
4 
   1         
mTOR-
inhibitors 
2.
5 
0.5, 
11.2 
0.2
4 
   1.0
6 
0.4, 
2.7 
0.90       
Steroids 1     1     
Post-
transplant 
complications 
         
Rejection1 2.
6 
0.9, 
7.3 
0.0
9 
2.
7 
0.9, 
7.8 
0.0
7 
1.2 0.5, 
2.9 
0.62       
CMV 
infection/dise
ase1 
2.
4 
0.8, 
7.3 
0.1
1 
2.
2 
0.7, 
6.6 
0.1
6 
1.8 0.8, 
3.9 
0.15       
Serologies                
CMV, D+R- vs 
other 
0.
7 
0.2, 
3.2 
0.6
6 
   1.4 0.6, 
3.4 
0.50       
Toxoplasmosis
, D+R- vs other 
0.
3 
0.04, 
2.6 
0.2
9 
  0.2 0.03, 
1.9 
0.17     
Comorbidities 
at SOT 
         
Diabetes 
Mellitus 
2.
4 
0.8, 
7.1 
0.1
2 
   0.9 0.3, 
2.6 
0.90       
Chronic Renal 0. 0.2, 0.4    1.4 0.6, 0.42       
A
cc
ep
te
d 
A
rt
ic
le
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Insufficiency 6 1.8 1 3.1
BMI at SOT 0.
9 
0.9, 
1.1 
0.8
5 
  1.0 0.9, 
1.1 
0.72     
Primary 
Pneumocystis-
prophylaxis 
0.
5 
0.15, 
1.9 
0.3
3 
   0.4 0.2, 
0.9 
0.02 0.6 0.2, 
1.4 
0.20 0.
4 
0.17, 
0.9 
0.0
4 
 
OR: Odds Ratio, 95% CI: 95% Confidence Interval, P: P-value, SOT: Solid Organ Transplant, IS: Immunosuppression, CMV: 
Cytomegalovirus, D: Donor, R: Recipient, BMI: Body Mass Index.  
 
Only variables with P-value>0.12 in univariable analyses were considered in the multivariable analyses.  
1 Rejection included the first episode of any type of acute rejection (cell- or antibody-mediated) and CMV infection/disease 
that required treatment during the first 6 months post-transplant.  
2 A second multivariable analysis-II was performed after excluding the variables associated with SOT type and year, to avoid 
potential interactions between these independent variables and administration of prophylaxis.  
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